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ABSTRACT: JMJD6 is known to localize in the nucleus, exerting histone arginine demethylase and lysyl hydroxylase
activities. A novel localization of JMJD6 in the extracellularmatrix, resulting from its secretion as a soluble protein,
was unveiled by a new anti-JMJD6 mAb called P4E11, which was developed to identify new targets in the stroma.
Recombinant JMJD6 binds with collagen type I (Coll-I), and distinct JMJD6 peptides interfere with collagen
fibrillogenesis, collagen-fibronectin interaction, andadhesionofhuman tumor cells to the collagen substrate. P4E11
and collagenbinding to JMJD6aremutually exclusivebecause the aminoacid sequences of JMJD6necessary for the
interactionwithColl-I are part of the conformational epitope recognized byP4E11. Inmice injectedwithmouse 4T1
breast carcinoma cells, treatment with P4E11 reduced fibrosis at the primary tumor and prevented lungmetastases.
Reduction of fibrosis has also beendocumented in humanbreast and ovarian tumors (MDA-MB-231 and IGROV1,
respectively) xenotransplanted into immunodeficient mice treated with P4E11. In summary, this study uncovers a
newlocalization and function for JMJD6 that ismost likely independent from its canonical enzymatic activities, and
demonstrates that JMJD6 can functionally interact with Coll-I. P4E11 mAb, inhibiting JMJD6/Coll-I interaction,
represents a new opportunity to target fibrotic and tumor diseases.—Miotti, S., Gulino, A., Ferri, R., Parenza,
M.,Chronowska,A., Lecis,D., Sangaletti, S., Tagliabue,E., Tripodo,C.,Colombo,M.P.Antibody-mediatedblockade
of JMJD6 interaction with collagen I exerts antifibrotic and antimetastatic activities. FASEB J. 31, 5356–5370 (2017).
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Thevariety of stromal cells andextracellularmatrix (ECM)
components contributes to the complexity of tumor mi-
croenvironment. ECMis constitutedby secreted structural
proteins including collagens, fibronectin (Fn), proteo-
glycans, and laminins, which form a network that pro-
vides mechanical support and controls cell proliferation,
adhesion, and migration (1). Other components of ECM
are constituted by matricellular proteins that, although
not endowed with structural functions, contribute to
the regulation of cell–ECM interactions. Among the
matricellular proteins, the secreted protein acidic and
rich in cysteine (SPARC) displays a pivotal function in
ECM assembly, particularly of fibrillar collagen, and in
Fn-induced integrin-linked kinase activation and sig-
naling (2).Other secretedproteins that belong to the lysyl
oxidase family are involved in the formation of covalent
intra- and intermolecular cross-links between collagen
secreted microfibrils (3), which increase matrix stiffness
and tumor progression (4, 5).
Collagen post-translational modifications start dur-
ing its biosynthesis, which occurs inside the endoplas-
mic reticulum. The Fe2+- and 2-oxoglutarate-dependent
oxygenases are responsible for collagen modification
by hydroxylating the proline (C-3 and C-4) and lysine
residues (C-5), which both contribute to triple helical
collagenstabilization (6).The2OG-dependentoxygenases
constitute a large family of enzymes with a highly
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conserved structure and catalyze awide range of oxidative
reactions inmicrobes andplants. Two enzymatic activities,
hydroxylation anddemethylation ofN-methylated groups
within proteins and nucleic acids, have been identified in
animals (7). The 2OG-dependent oxygenases belong to the
JmjC subfamily (8), the members of which play a central
role in the epigenetic regulation of gene expression during
embryonic development and stem cell differentiation (9,
10). In tumors, their overexpression is associated with ag-
gressive phenotype and cancer stem cell plasticity (11, 12).
JMJD6 is a member of the JmjC family. It was initially
considered to be a transmembrane receptor specific for
phosphatidylserine (PS) and necessary for the recognition
of apoptotic cells by macrophages (13). Nevertheless, the
presence of multiple nuclear localization signals in the
protein sequence (14), its nuclear localization in trans-
fected cells (15), its histone arginine demethylase activity
(16), and the interaction with single-strand RNA (17),
taken together, suggested a more complex role of JMJD6.
Accordingly, it has been demonstrated more recently that
JMJD6 targetsanumberofproteins, suchasRNA-splicing-
associated factors, histones, and p53 (18–20), through its
lysyl hydroxylase activitywhile itmodifies other proteins,
such as ERa andHSP-70, through its demethylase activity
(21, 22). Inmice, JMJD6 knockout is lethal (23), supporting
the idea that this enzyme plays a pivotal role during de-
velopment. Moreover, JMJD6 overexpression in breast
cancers is associated with poor prognosis (24), and its ec-
topic expression increases cancer cell line proliferation
while its silencing reduces cell growth, motility, and in-
vasion (24, 25). Through alternative nonenzymatic activi-
ties, JMJD6 modulates RNA splicing by interacting with
the arginine–serine (RS) domains of SR and SR-like pro-
teins (26) and controls adipocyte differentiation through
transcriptional and post-transcriptional mechanisms (27).
In order to develop antibodies against molecules in-
volved in stromal tissue modifications, we immunized
Sparc-null mice, which display defective ECM organiza-
tionand tissue remodeling,withwild-type tissueswith the
idea that these mice could immunologically recognize
novel ECM structures generated in the presence of the
matricellular protein SPARC. Using this approach, we
isolated a mAb (P4E11) specific for JMJD6 and uncovered
anewextracellular localizationof JMJD6.Furthermore,we
demonstrated that JMJD6 functionally interacts with col-
lagen within the ECM and that this interaction can be
inhibited by our novel P4E11 mAb.
MATERIALS AND METHODS
Reagents and antibodies
All reagents were a high-purified grade, and, if not otherwise
specified, were purchased from Sigma-Aldrich (St. Louis, MO,
USA). Purified recombinant JMJD6 (rJMJD6) protein (transcript
variant 2, TP 308993) and the anti-DDKmAbrecognizing aFLAG
epitope on rJMJD6 protein were from OriGene Technologies
(Rockville, MD, USA). Rat collagen type I (Coll-I) was purchased
from BD Pharmingen (San Diego, CA, USA) (354236). Collagen
type IV (Coll-IV)murinesarcoma (C0543), Fn frombovineplasma
(F4759)andbovineserumalbumin (BSA)wereallpurchased from
Sigma-Aldrich. The following anti-JMJD6 Abs were used: mouse
mAb:SantaCruzBiotechnology (sc-28348) (SantaCruz,CA,USA);
rabbit polyclonal Abs: Sigma-Aldrich (P1495), Abcam (Cam-
bridge, MA, USA) (ab64575), and Abnova (Taipei, Taiwan)
(PAB2219).Anti-Coll-IAbswere fromSigma-Aldrich (mousemAb
C2456, rabbit polyclonal anti-humana2 chain, SAB4500363), from
Merck Millipore (Billerica, MA, USA) (rabbit polyclonal AB765P),
and from Santa Cruz Biotechnology (mouse mAb recognizing
mousea2 chain, sc-393573). The rabbit polyclonalAbs anti-Coll-IV
and anti-Fn were from Abcam (ab6586) and Sigma-Aldrich
(F3648), respectively; mAbs anti-CD63 and anti-GAPDH were
from Abcam (ab8219) and Sigma-Aldrich (G8795), respectively.
The mouse mAb anti-Rab11 was from BD Transduction Labora-
tories (Lexington, KY, USA) (610657). Biotin rat anti-mouse CD45
(clone 30-F11) was from BD Pharmingen. Depending on the ap-
plication, different purified IgG2a mAbs [553454 and W632, BD
Pharmingen; HB-95, American Type Culture Collection(ATTC),
Manassas, VA, USA] were used as isotypic control.
For use of anti-JMJD6 antibodies, because P4E11 mAb dis-
played reactivity in immunoprecipitation but not inWesternblot
(WB) analyses,we used the rabbit polyclonal anti-JMJD6 (Sigma-
Aldrich) and the mAb (Santa Cruz Biotechnology) for WB
staining. In particular, the polyclonal Ab has been used to test
samples immunoprecipitated by P4E11mAb and themAb Santa
Cruz Biotechnology for directWB staining of cell samples and on
lipid blots. For immunofluorescence analysis of JMJD6 cellular
distribution, the rabbit polyclonal anti-JMJD6 (Sigma-Aldrich)
was used in double staining together with mAbs recognizing
endosomal markers (Rab11 and CD63).
Cell lines
The thioguanine-resistant 4T1 mouse breast carcinoma cell line
(CRL-2539; ATCC) was from LGC-Promochem (Teddington,
United Kingdom) (28, 29). The following human tumor cell lines
were obtained from ATCC: MDA-MB-231 (HTB-26), MCF7
(HTB-22), SKBR3 (HTB-30), SKOV3 (HTB-77), MeWo (HTB-65),
Jurkat (TIB-152), and U-937 (CRL-1953.2). The IGROV1 cell line
was provided by the laboratory of S. Canevari (Fondazione
IRCCS Istituto Nazionale dei Tumori); the A375M cell line (CRL
16199; ATCC) was provided by A. Care` (Istituto Superiore di
Sanita`, Rome, Italy); and the Mel 665.1 cell line was provided by
A. Anichini (Fondazione IRCCS Istituto Nazionale dei Tumori).
Cell lines were characterized by STR allele profile (D13S317,
D16S539, D21S11, D5S818, D7S820, TH01, TPOX, and vWA)
using theGeneprint 10 Systemkit (Promega,Madison,WI,USA).
Human and mouse cell lines were grown in RPMI 1640
medium and in DMEM, respectively, containing 1% glutamine
and 10% fetal bovine serum (FBS) (PAA Laboratories, Colbe,
Germany) in standard culture conditions (37°C and 5% CO2).
Cells were regularly checked for mycoplasma contamination
by the MycoAlert detection kit (Lonza, Basel, Switzerland),
with negative results.
Mice
BALB/c mice, aged 5 to 7 wk, were supplied by Charles River
Laboratories (Wilmington, MA, USA). BALB/c Sparc2/2 mice
were developed in our institute as previously described (30). All
animal treatments were authorized by the Institutional Ethics
Committee for Animal Use at Fondazione Istituto di Ricovero e
CuraaCarattere Scientifico (IRCCS) IstitutoNazionaledei Tumori.
Production of P4E11 mAb, and identification of
target protein and recognized epitope
In order to obtain antibodies directed against components of the
ECM, 2 Sparc2/2 mice lacking the matricellular protein SPARC
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were immunized twice with irradiated splenocytes deriving
from SPARC-competent BALB/c mice. Hybridomas resulting
from the fusion of splenic lymphocytes of one of themwith NS0
myeloma cells were selected by culture in hypoxanthine–
aminopterin–thymidinemediumand their supernatants assayed
by fluorescence-activated cell sorting analysis on permeabilized
murine cells expressing or not expressing SPARC protein.
Among these, P4E11 mAb (IgG2a) was chosen for a further
characterization.
To identify the target protein, themAbwas tested by Thermo
Fisher Scientific (Waltham, MA, USA) on a protein array (Pro-
toArray v.5.0; Thermo Fisher Scientfific) of 9400 human proteins.
JMJD6, which resulted in one of the best statistically significant
candidates, was validated by immunoprecipitation followed by
WB analysis. The specific epitope on rJMJD6 recognized bymAb
P4E11 was defined by differential mapping of rJMJD6 alone as
well as by rJMJD6 + mAb P4E11 and rJMJD6 + mAb W632
(isotype control) at the Protein Microsequencing Facility (San
Raffaele Scientific Institute, Milan, Italy).
P4E11 in vivo treatment
BALB/c mice, with each group consisting of 7 animals, were in-
oculated with 7 3 103 4T1 cells in the mammary fat, and the pri-
mary tumor growthwasmonitored for 4wk.Agroupofmicewas
treated intraperitoneally with purified P4E11 (250 mg/inoculum)
starting from the day before tumor injection twice a week for
4 wk. The control groups were treated with the same dose of
unrelated antibody of the same isotype as P4E11 (IgG2a) or
with saline. At the end of the treatment, animals were anes-
thetized and then humanely killed; the primary tumor was
evaluated for size and removed for histochemical analysis. The
approximate tumor volume was calculated by rminor
23 rmajor.
Lungs were used for histochemical analysis and for evaluation
of the metastatic disease in clonogenic assays, as described
elsewhere (28). MDA-MB-231 cells (53 106) were inoculated in
the mammary fat of immunodeficient SCID mice, and growth
was monitored for 3 to 4 wk. IGROV1 cells (5 3 106) were
inoculated intraperitoneally into immunodeficient nude mice,
and the growth was monitored for about 3 wk. In both cases,
the treatment groups (5 animals/group) included animals in-
oculated with P4E11 (same therapeutic regimen as above) and
control animals inoculated with saline. The histologic analysis
(Gomori reticulin and Masson trichrome staining) was con-
ducted on solid primary tumors of MDA-MB-231 and on
peritoneal adhering aggregates of IGROV1 cells.
Immunofluorescence on adherent cells
Cells seeded on glass slides were fixed with paraformaldehyde
2 to 4% for 20 min at room temperature and permeabilized with
0.1% Triton X-100 or 0.1% saponin as specified. Incubation with
primary and secondary (Alexa Fluor,Molecular Probes, Eugene,
OR,USA; Thermo Fisher Scientific) antibodieswas performed as
described (31). Samples were analyzed by confocal microscopy
(Micro Radiance 2000; Bio-Rad, Hercules, CA, USA). Images
were obtained using a 360 oil immersion objective (512 3 512
pixels) by LaserSharp 2000 software (Carl Zeiss GmbH, Jena,
Germany) and processed by Image-Pro Plus 7 software (Media
Cybernetics, Rockville, MD, USA). Reported images represent a
single central section on the z axis.
Histology and immunohistochemistry
Mouseandhumantissueswere fixed in10%buffered formalinand
embedded inparaffin.Histopathologic analysiswasperformedon
4 mm sections stained with hematoxylin and eosin, Gomori retic-
ulin, andMasson trichrome.Human samples comprised formalin-
fixedbreast carcinomaspecimensthatwerepartofastudyonECM
composition (32) carriedout inour institutebyE.T.underapproval
from the local ethics committee and in accordance with the Hel-
sinki Declaration. Human melanoma and colon carcinoma were
archival samples stored at the Human Pathology Section, Uni-
versity of Palermo, Palermo, Italy.
Immunohistochemistry was performed after antigen
unmasking usingNovocastra Epitope Retrieval Solutions pH 9
(Novocastra, Leica Biosystems, Wetzlar, Germany) using the
PT Link system (Dako, Glostrup, Denmark) at 98°C for 30 min.
Subsequently the sections were brought to room temperature
and washed in phosphate-buffered saline (PBS). After neu-
tralization of the endogenous peroxidase with 3%H2O2 and Fc
blocking by a specific protein block, the samples were in-
cubated for 1 h with the following primary antibodies: mouse
mAb P4E11 (5 and 7 mg/ml); mouse mAb anti-JMJD6 (Santa
Cruz Biotechnology) (4mg/ml);mousemAbanti-humanColl-I
(clone 3G3; Acris, Herford, Germany) (5 mg/ml); and mouse
mAb anti-human Coll-IV [clone 24.12.8 (PHM-12); Merck
Millipore] (10 mg/ml), all at 4°C. Staining was revealed by the
polymer detection kit method (Novolink Polymer Detection
Systems, RE7280-K; Novocastra, Leica Biosystems) and AEC
(3-amino-9-ethylcarbazole) substrate chromogen. The slides
were counterstained with Harris hematoxylin (Novocastra,
Leica Biosystems). Negative control stainings were performed
by usingmouse and rabbit immune sera instead of the primary
antibodies. All the sections were analyzed under a DMD 108
optical microscope (Leica Microsystems, Buffalo Grove, IL,
USA), and microphotographs were collected with the Axio
Scope.A1 Axiocam 503 Color (Zeiss).
ELISA and JMJD6 peptide library
For ELISA tests, a library of 57 JMJD6 peptides, 14 aa long and
overlapping each other for 7 aa, was synthesized by Primm
(Milan, Italy). In each assay, the catcher protein, diluted in PBS at
the proper concentration, was seeded in 96-wells plate and in-
cubatedONat 4°C.After saturationwith 1%BSA inPBS, specific
incubations were carried out with soluble rJMJD6 or ECM pro-
teins and then with secondary horseradish peroxidase (HRP)-
conjugated antibodies (Zymed Laboratories, San Francisco, CA,
USA; Thermo Fisher Scientific). All incubations were at room
temperature, followed by 3 washings by PBS–0.1% Tween 20.
The reaction was developed from tetramethylbenzidine (Sigma-
Aldrich), stoppedwith 1 NH2SO4, and the plate read at 450 nm.
To test the capability of JMJD6 peptides to inhibit the in-
teraction between Coll-I and rJMJD6, Coll-I was mixed with each
peptide pool in 1000 times molar excess (the composition of each
peptide pool is described in Supplemental Fig. S3C), and then
incubated for 30 min at 37°C before seeding on plate ON at 4°C.
Details of each assay are reported in the respective figure captions.
ECM extraction, and cell lysate and
supernatant preparation
Overconfluent human cell line plates were treated with 20 mM
NH4OH in distilled water to eliminate the cell component. After
washings, plateswere treatedwith 1%SDScontainingbuffer and
scratched to recover ECM proteins.
Cell lysates were obtained by treatment of the cells with lysis
buffer containing 1% NP-40, 0.1% SDS, protease, and phospha-
tase inhibitors for 30 to 40 min on ice. The soluble fraction was
recovered by centrifugation for 15 min at 13,000 rpm.
Culture supernatantswere obtained from cells grown for 24 h
at 37°C in medium without FBS and processed by differential
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centrifugations (10 min at 1300 rpm, then 20 min at 2600 rpm).
Protein content was evaluated by the bicinchoninic acidmethod
(Thermo Fisher Scientific, Waltham, MA, USA) or alternatively
by Bradford assay (Quick assay; Bio-Rad).
For other analyses, MeWo cell supernatant was also sub-
mitted to centrifugation (30 min at 10,000 g) and then to ultra-
centrifugation (2 h at 100,000 g) to obtain a soluble fraction (Su)
and a pellet (Pu). All the samples, before and after processing,
were analyzed by WB, as previously described.
To test the factorswhich stimulate JMJD6 release,MeWo cells
were treated for 17 h with medium without FBS containing
brefeldin A (BFA) (5 mg/ml), ionomycin (Iono) (1 mg/ml), or
DMSO (1:1000) as a control. At the end of the treatment, the
supernatantwas recovered and submitted to centrifugations and
concentration as previously described for WB analysis.
SDS-PAGE, WB analysis, and immunoprecipitation
SDS-PAGE sample analysis, protein transfer, and immuno-
reactions as well as the immunoprecipitation experiments were
carried out essentially as described elsewhere (31). For immu-
noprecipitation experiments, P4E11 and isotype control mAb
were conjugated to epoxy-activated magnetic beads (Thermo
Fisher Scientific). To test the interaction of Coll-I with rJMJD6,
Coll-I (5 mg) was separated in SDS-PAGE under reducing
conditions. After blotting, the membrane was stained red by
Ponceau S, or saturated and incubatedwith rJMJD6, thenwith
a primary anti-FLAG (DDK) mAb recognizing JMJD6 and
subsequently with secondary HRP-conjugated anti-mouse
antibodies before ECL. As a control, the anti-DDK reactivity
was evaluated in the absence of rJMJD6. In parallel, the same
amount of Coll-I was immunostained with anti-Coll-I anti-
bodies with different specificity.
Silencing of JMJD6 expression by short interfering
RNA transfection
MeWo cells (4.43 105 per sample) were grown for 24 h at 37°C,
then transfected asdescribed (31)with amixof 2 short interfering
RNA (siRNA) duplexes specific for JMJD6 (Trilancer-27 human
siRNA;OriGene Technologies) orwith unrelated scrambled (scr)
negative control siRNA using Lipofectamine 2000 (Thermo
FisherScientific). Seventy-twohoursafter removalof transfection
reagents, cells were solubilized for immunoprecipitation with
P4E11 mAb andWB.
Knockout of JMJD6 through clustered
regularly interspaced short palindromic
repeat/Cas9 technology
JMJD6 knockout MDA-MB-231 cells were obtained with clus-
tered regularly interspaced short palindromic repeat (CRISPR)/
Cas9 technologyasdescribedbyRan et al. (33).ThehumanJMJD6
genomic sequence was analyzed with the CRISPR Design Tool
(http://tools.genome-engineering.org) to identify potential genomic
RNA targets, which were cloned in the pSpCas9(BB)-2A-GFP
plasmid (ID 48138; a gift from F. Zhang, Addgene, Cambridge,
MA, USA). MDA-MB-231 cells were then transfected with
Lipofectamine 3000 reagent (Thermo Fisher Scientific) by
using the pSpCas9(BB)-2A-GFP plasmid containing the 59-
GCTCTCGTAGTAGTTGTGCC-39 genomic RNA (specific for
JMJD6) ormock transfectedwith empty vector. After 48 h, green
fluorescent protein–positive cells were sorted by fluorescence-
activated cell sorting, and single cells were seeded in 96-well
plates.Cloneswere then screened byWBandpotential knockout
clones further validated by sequencing.
Lipid blot immunoreaction
Nitrocellulosemembranewithphospholipid spots (PIP strips,
100 pM; Echelon Biosciences, Salt Lake City, UT, USA) was
saturated with 3% BSA in PBS, then incubated with rJMJD6
(0.5 mg/ml) in the same buffer. After 2-h incubation, the re-
action proceeded by incubating with the primary anti-FLAG
(DDK) or aJMJD6 mAb and secondary HRP-conjugated Abs,
as described above for WB. As a control, a strip not incubated
with rJMJD6was stainedwith anti-FLAG and secondary anti-
mouse Abs only.
Cell fractionation
Confluent MeWo cells, washed in PBS, were detached by
scraping and lysed in hypotonic buffer HB-7S (5 mMTris, 1 mM
EDTA, 1 mMDTT, and 11% sucrose, pH 7.4), and processed by
differential centrifugations as previously described (31) to obtain
a final pellet considered the nuclear fraction and a supernatant,
cleared of the crude membrane fraction, which constituted the
cytosolic fraction.
Inhibition of cell adhesion by JMJD6 peptides
The assay was carried out to evaluate the adhesion of tumor
cells (MDA-231, MeWo) to Coll-I substrate alone or mixed
with JMJD6 or scr peptides in 100 times molar excess. Ad-
hesion was evaluated after 2, 6, or 24 h incubation at 37°C.
The adhesion to peptides alone in the absence of Coll-I was
also tested. The percentage of cell adhesion at each time
point was calculated considering the adhesion on Coll-I
mixed with scr peptides as 100%.
Inhibition of fibrillogenesis by JMJD6 peptides
Rat Coll-I was diluted in 0.02 N acetic acid to obtain a soluble
preparation. To induce the formation of insoluble fibrils, pHwas
increased to 7.4 by addition of Tris-HCl buffer, pH 8.3. After
30 min incubation at room temperature, the insoluble collagen
was separated from the soluble one by centrifugation for 10 min
at 13,000 rpm.The recovered supernatant and thedrypelletwere
analyzed by SDS-PAGE. Gels were stained by Simply Blue (GE
Healthcare Life Sciences, Little Chalfont, United Kingdom). To
evaluate whether JMJD6 peptides could interfere with Coll-I
fibrillogenesis, each pool of peptides was mixed in 1003 molar
excesswith Coll-I diluted in acetic acid, then Tris-HCl buffer, pH
8.3,was added.After incubation for 30min at room temperature,
samples were processed as described above. The percentage of
soluble collagen in the supernatantwas evaluated takingas 100%
the amount of Coll-I present in the supernatant of Coll-I diluted
in acetic acid.
Statistical analysis
One-way ANOVA and unpaired, 2-tailed Student’s t test were
used for statistical analysis.
RESULTS
JMJD6 is detectable in ECM in vitro and in vivo
To identify new targets within the tumor stroma that are
potentially amenable for antibody-mediated treatments,
we immunized Sparc-null mice with tissues derived from
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syngenic wild-type BALB/c mice. Using this approach,
we obtained a mAb, referred to as P4E11, which recog-
nized an antigen expressed by permeabilized mouse and
human tumor cell lines of different histotypes (data not
shown). An array of over 9000 human proteins indicated
JMJD6 as the most likely target of P4E11; this was con-
firmed by immunoprecipitation experimentswith rJMJD6
protein and tumor cell lysates (Fig. 1A). Specificity for
JMJD6 was further confirmed by using MeWo cells si-
lenced for JMJD6 expression and isogenic MDA-MB-231
cells either positive or negative for JMJD6 because
of CRISPR/Cas9-mediated knockdown (Fig. 1B). In
immunoprecipitation experiments, P4E11 recognized
the monomeric form of JMJD6 (50 kDa) as well as high-
molecular-weight oligomers (120–200 kDa). Because
P4E11 also recognizes human JMJD6, we tested its
reactivity in 22 cases of breast carcinoma, already
characterized for ECM composition (32). As for the
representative cases shown in Fig. 2A, P4E11 mAb
widely reacted with tumoral and stromal cellular ele-
ments, as well as with the ECM, as reported in Supple-
mental Table 1. High JMJD6 expression was observed in
tumors (12 of 22 had the highest score of 3+, with 70 to
100% of cells stained), while the staining of ECMwas less
intense, with only 7 of 22 cases scored as 3+ and 11 of 22
samples classified as 1+. Most of these 1+ cases were
characterized by a diffuse pattern of staining (8 of 11).
The tissue immunolocalization of JMJD6 in the same 22
breast carcinomas stained with P4E11 mAb was con-
firmed using a commercial anti-JMJD6 mAb (Supple-
mental Fig. S1), which, however, displayedmore intense
and frequent nuclear staining. WB analysis, performed
on the ECM extracted from plates after cell removal by
hypotonic lysis (Fig. 2B), further supported ECM local-
ization of JMJD6 in a panel of human tumor cell lines.
These results demonstrated that P4E11 mAb recognizes
JMJD6, which can also be detected in the extracellular
milieu associated with the ECM.
Figure 1. Speciﬁcity of P4E11 mAb for JMJD6. A) Validation of ProtoArray results by immunoprecipitation of recombinant JMJD6
(rJMJD6) (left) and tumor cell lysates (right) by P4E11 mAb (P4) and by control isotypic mAb (C). B) Immunoprecipitation of
MeWo and MDA-231 cell lysates before and after inhibition of JMJD6 expression by siRNA (left) or CRISPR/Cas9 knockout
(right), respectively. All WB analyses were carried out by polyclonal aJMJD6 Ab (Sigma-Aldrich). Arrows indicate JMJD6
monomeric and oligomeric forms of JMJD6 recognized by P4E11 mAb. Asterisks indicate immunoglobulin H and L chains from
immunoprecipitating mAb.
5360 Vol. 31 December 2017 MIOTTI ET AL.The FASEB Journal x www.fasebj.org
Downloaded from www.fasebj.org by (147.163.68.12) on March 05, 2018. The FASEB Journal Vol. 31, No. 12, pp. 5356-5370.
JMJD6 is secreted as soluble protein
To investigate whether JMJD6 could be secreted, the su-
pernatants fromthe samepanelofhuman tumorcellswere
tested by WB for the presence of JMJD6 and compared to
their respective cell lysates. All cell lysates and superna-
tants contained both the 50-kDa monomer and the high-
molecular-weight oligomers (120–200 kDa) of JMD6 (Fig.
3A) as already observed in the immunoprecipitation ex-
periments (Fig. 1).
The extracellular localization of JMJD6 was not pre-
dictable because it lacked the signal-peptide typical of
secreted proteins. Nevertheless, even after ultracentri-
fugation, the supernatant (Su) of MeWo cells contained
both JMJD6 monomer and oligomers in soluble form
(Fig. 3B), though a small fraction of JMJD6 was also
detected in the CD63-positive pellet (Pu), which
contained the exosome fraction. Soluble JMJD6was also
detected after ultracentrifugation in the supernatants of
other human (Jurkat) and mouse (4T1) tumor cell lines
(Supplemental Fig. S2A). In MeWo cells, neither the
intracellular retention nor the block of secretion was
induced by BFA, which instead inhibited Fn secretion
that proceeds via Golgi vesicles (Fig. 3C). In contrast,
treatment with the Ca2+ ionophore Iono induced a re-
markable release of JMJD6 but negligible Fn secretion
(Fig. 3C). Coll-I, which is normally secreted via Golgi
vesicles, was not detectable in the supernatant of un-
treated or BFA-treated cells. Interestingly, Iono also
induced the release of Coll-I. Taken together, these data
show that cytoplasmic JMJD6 can be unconventionally
secreted, as soluble protein, into the extracellular space,
and that increased intracellular Ca2+ concentration
stimulates its externalization.
Figure 2. Reactivity of P4E11 mAb on ECM of human breast carcinoma and tumor cell lines. A) Immunohistochem-
ical staining of 4 representative human breast carcinoma specimens as evaluated by P4E11 mAb. Scale bars, 100 mm.
Magniﬁcation of extracted area, 32. B) WB analysis of ECM proteins extracted from culture ﬂasks of overconﬂuent human
tumor cell lines compared to MeWo cell lysate (Ly). For each cell line, same volume of extracted 103 concentrated
proteins was analyzed. Ly = 15 mg. Immunostaining of JMJD6 by anti-JMJD6 mAb (Santa Cruz Biotechnology). Staining of
extracted ECM components, Coll-I and Fn, as positive control. a-Tubulin content monitored for possible presence of
residual intracellular proteins. Arrows indicate monomeric and oligomeric forms of JMJD6, and mature and cleaved forms
of Coll-I.
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Figure 3. JMJD6 secretion, nucleo- or cytoplasmic localization, interaction with phospholipids, and association with intracellular
vesicles. A) WB of cell lysates (left) and culture supernatants (right) of human tumor cell lines. Cell lysates = 15 mg; supernatants =
30 mg. Control for gel loading: actin content (lysates), red Ponceau S staining (supernatants). All WB analyses (A–D) were
performed with anti-JMJD6 mAb (Santa Cruz Biotechnology). B) WB of MeWo cell lysates (Ly), of culture supernatants before
(continued on next page)
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Cytoplasmic JMJD6 associates with
intracellular vesicles
Biochemical fractionation and immunofluorescence stain-
ing demonstrated that JMJD6 is present in both the cyto-
plasm and the nuclei of MeWo cells (Fig. 3D, E). Some
cytoplasmic proteins can be externalized through the in-
teraction with lipids present in the membrane of in-
tracellular vesicles. Protein sequence analysis of JMJD6
identified thepresence of theK/RX(3-5)K/RXK/RK/R (aa
84–92) consensus sequence (34), which is functional for the
binding to phospholipids (Supplemental Fig. S2B) and
which differs from the sequence recently described in
Caenorhabditis elegans as responsible for interactionwith PS
(35). Recombinant JMJD6 showed preferential interaction
with phosphatidic acid (PA) and a much weaker in-
teraction with PS and the inositol phosphates PI(4)P and
PI(5)P (Fig. 3F). We subsequently stainedMeWo cells with
both anti-JMJD6 antibody andvesicle-specificmarkers and
observed colocalization signals relative to JMJD6 and the
recyclingendosomemarkerRab11,particularlyaround the
microtubule organizing center (36), as well as between
JMJD6 and CD63 (Fig. 3G). Rare foci of costaining were
observed between JMJD6 and the early endosomalmarker
Rab5 (data not shown). These results confirm that JMJD6 is
not only present in the cytoplasm as a soluble protein but
also associates with intracellular vesicles marked by CD63
and Rab11, which might act as vehicles for JMJD6
externalization.
Interaction of rJMJD6 with ECM components
Having identified JMJD6 within the ECM, we tested
whether recombinant rJMJD6 could directly bind with
ECM components such as Coll-I and Fn seeded on plate.
Serial dilutions (100, 10, and 1 nM) of flagged rJMJD6
showed a steady binding with rat Coll-I but a declining
dose-dependent reactivity with Fn and no reactivity with
BSA (Fig. 4A). To further test the specificity and sensitivity
of this interaction, plates were coated with serial dilutions
of rat Coll-I, Coll-IV, Fn, and BSA, starting from 50 pMper
well, and incubatedwitha fixeddoseof rJMJD6 (10nM). In
these conditions, rJMJD6 stably binds to Coll-I diluted to
0.08 pM/well, whereas the binding to Coll-IV and Fn im-
mediately dropped and was abolished at a concentration
of 2 pM per well (Fig. 4B). Because of rJMJD6 interaction
with purified rat and human Coll-I on the plate (data not
shown),both collagenswereanalyzedbySDS-PAGEunder
reducing conditions to obtain the distinct a1 and a2 chains
(Fig. 4C). After blotting on nitrocellulose membrane, anti-
FLAG (DDK) mAb revealed that rJMJD6 selectively binds
to the a1 chain of both rat and human Coll-I.
Identification of JMJD6 sequences mediating
Coll-I interaction
A 14 aa JMJD6 peptide library covering the entire protein
sequence was tested on a plate for recognition by the
polyclonal and monoclonal anti-JMJD6 antibodies, which
detect the intact recombinant JMJD6 protein (Supple-
mental Fig. S3A, inset). While the polyclonal Ab recog-
nizedpeptides 52–54 (aa 358–385 of theprotein) according
to its specificity (immunizing peptide aa 363–381), no re-
activity was detected by the commercial mAb, suggesting
that it could recognize a conformational epitope, which is
lost when the whole sequence is broken into fragments
(Supplemental Fig. S3A). Also, the P4E11 mAb could rec-
ognize a conformational epitope. In fact, it is unable to
react against any single peptide and even against the intact
rJMJD6 that had previously been fixed on the plate.
Nonetheless, the P4E11 mAb detects the JMJD6 soluble
form.
We then tested whether any of these peptides could
bindColl-I. Peptideswere seededonaplate and incubated
with rat Coll-I at the highest dose used in the assay re-
ported in Fig. 4B. A polyclonal Ab against mouse Coll-I
revealedColl-I binding tomultiple JMJD6peptides,with 5
peaks of reactivity inside and4outside of the JmjCdomain
(Fig. 5A). No Coll-I reactivity was detected on 2 scr pep-
tides used as controls. In addition, the use of Fn instead of
Coll-I in the same assay did not show any binding of Fn
to JMJD6 peptides (Supplemental Fig. S3B). We sub-
sequently tested whether the pools of peptides (Supple-
mental Fig. S3C), corresponding to the above-defined
peaks of interaction, could inhibit the binding of the
rJMJD6 to Coll-I. Although tested in a stronger molar ex-
cess (1000 times) than Coll-I, no peptide pool proved to
inhibit rJMJD6 binding when Coll-I was preseeded on
wells (Supplemental Fig. S3D). Conversely, when JMJD6
peptide pools were mixed at 37°C with Coll-I before their
(S) and after (Su) ultracentrifugation, and of corresponding pellet (Pu). Ly = 15 mg. S = 30 mg and equivalent volume of Su and Pu
samples. Distribution of exosome marker evaluated by anti-CD63 mAb. C) WB of MeWo cell lysates and supernatants upon
treatment with BFA or Iono compared to DMSO-treated control cells. Coll-I and Fn content used as positive control of
conventionally secreted proteins. Actin expression (Ly) and red Ponceau S staining (Sup) were used as controls for gel loading.
D) JMJD6 distribution in cytoplasmic (Cy) and nuclear (Nu) fractions of MeWo cells. Enrichment for cytoplasmic (a-tubulin) and
nuclear (lamin A/C) markers evaluated in each fraction compared to cell lysate. Graphic illustrates relative distribution of
JMJD6 (50-kDa band), lamin, and a-tubulin in nuclear and cytoplasmic fraction, as evaluated by densitometry analysis.
E) Immunoﬂuorescence staining and confocal microscopic analysis of MeWo cells by polyclonal anti-JMJD6 Ab (Sigma-
Aldrich). Differential cell permeabilization by 0.1% Triton X-100 (top) and 0.1% saponin (bottom) to highlight nuclear or
cytoplasmic JMJD6 localization, respectively. Nuclei are stained by DRAQ5. Single central section on z axis is reported. Scale
bar, 20 mm. F) Interaction of rJMJD6 with phospholipids on nitrocellulose membrane as revealed by anti-FLAG (DDK) Ab or
anti-JMJD6 mAb (Santa Cruz Biotechnology). Control membrane incubated with anti-FLAG mAb in absence of rJMJD6. G)
Immunoﬂuorescence staining and confocal analysis of MeWo cells permeabilized by 0.1% Triton X-100 (left) or 0.1% saponin
(right) and double stained with anti-JMJD6 polyclonal Ab (Sigma-Aldrich) (red) and mAbs recognizing endosomal markers
Rab11 and CD63 (green). Nuclei are stained by DRAQ5. Single central section on z-axis is reported. Scale bars, 20 mm. Yellow
arrows indicate Rab11/JMJD6 costaining near microtubule organizing center.
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seeding on a plate, both inhibition and enhancement of
rJMJD6 bindingwere observed, depending on the peptide
pools tested (Fig. 5B). Pools containing sequences be-
longing to the JmjC domain displayed limited or no in-
hibition of rJMJD6 binding to Coll-I, whereas those
included into the external regions of the protein, either
N- or C-terminal, enhanced the interaction between
rJMJD6 and Coll-I up to 2- to 3-fold (Fig. 5B). As a
control, scr peptide pool mixed to Coll-I did not modify
the binding of rJMJD6 to Coll-I. These results were
consistent in 4 distinct experiments for all peptide pools
except for pool F, the activity of which varied widely
among the experiments.
To further investigate the interaction between specific
regions of JMJD6 protein and Coll-I, we performed an in
vitro fibrillogenesis experiment. Using this assay,we tested
whether pools of JMJD6 peptides (A, B, E, and I) mixed to
Coll-I could interferewith fibrillogenesis. Compared to the
Coll-I/scr peptidemix showingdecreased soluble collagen
from 100 to 12% at physiologic pH, the mix containing the
peptide pool I—and, less efficiently, pool A—maintained
the collagen soluble at 46.87 and 26.4%, respectively, thus
antagonizing fibril formation (Fig. 5C).
In summary, we demonstrated that a mechanical in-
teractionbetween JMJD6andColl-I takesplace in vitro and
that this interaction can modify Coll-I behavior. This
suggests that the binding of JMJD6 peptides to Coll-I
during fibrillogenesis could influence the interaction with
other proteins present in the ECM. To test this hypothesis,
we investigated the effects of JMJD6 peptides on the in-
teraction between Coll-I and Fn.
JMJD6 peptides modulate Coll-I/Fn interaction
and collagen-mediated cell adhesion
Fn interacts with Coll-I in vivo and contributes to ECM
stabilization.We testedwhether the binding of Fn toColl-I
could be inhibited by any of JMJD6 peptide pools pre-
mixed with Coll-I at 37°C. Pool C and especially pool G
inhibited the Fn binding to Coll-I (26.8% and 81.8%, re-
spectively) when used at 1000 times excess (Fig. 5D), thus
confirming our hypothesis.
Both Coll-I and Fn contribute to cell-substrate adhesion
through integrin-mediated recognition of specific se-
quences. We hypothesized that JMJD6 peptides mixed
with Coll-I could modulate cell adhesion interfering with
cell–collagen interaction. In agreement with our notion,
the JMJD6 peptides corresponding to pools A, B, H, I, and
F reduced the short-term (2 h) adhesion of the breast car-
cinoma cell lineMDA-MB-231 to the Coll-I substrate from
100%of control scrpeptidepool to61.8, 51.3, 64.5, 46.9, and
56.8%, respectively (Fig. 5E). Moreover, the inhibition
mediated by peptide pools A, B, and I was persistent all
along the observation time of 24 h (Fig. 5F). The seeding of
the sole peptide pools, in the absence of Coll-I, was in-
sufficient to block MDA-MB-231 cell adhesion (Supple-
mental Fig. S3E). Comparable results were obtained
investigating the short-term adhesion of the human mel-
anoma cell line MeWo (Supplemental Fig. S3F). These re-
sults indicate that specific JMJD6 peptides impair both
collagen binding to Fn and cell adhesion.
P4E11 mAb binding to rJMJD6 is mutually
exclusive from Coll-I
In light of the above-reported results, we reevaluated the
P4E11 mAb, which displayed reactivity in immunopre-
cipitationbutnot inWBanalyses.Accordingly, the epitope
recognized on rJMJD6 proved to be sensitive to heat de-
naturation (Supplemental Fig. S4A). Moreover, binding of
P4E11 to soluble rJMJD6was impairedwhen another anti-
JMJD6 antibody engaged the recombinant protein first
(Fig. 6A, column 2). However, the primary interaction of
P4E11 with rJMJD6 left the JMJD6 recognition unchanged
by thisAb(Fig. 6A, column1).This suggests that there isno
competition for the same epitope but rather that P4E11
recognizes a distinct epitope on JMJD6, the conformation
of which could be modified through the interaction with
Figure 4. JMJD6 binding to Coll-I. A) ELISA on ECM proteins showing binding of rJMJD6 (100, 10, 1 nM) to Coll-I (solid circles)
and Fn (open squares) in plate (50 pM/well) revealed by anti-FLAG (DDK) mAb. BSA (solid squares) was negative control. B)
ELISA showing binding of 10 nM rJMJD6 to serial dilutions of Coll-I (solid circles), Coll-IV (open circles), and Fn (open squares)
seeded in plate starting from 50 pM per well. Interaction was revealed by anti-FLAG (DDK) mAb. BSA (solid squares) was used as
negative control. C) Interaction of rJMJD6 with blotted rat and human Coll-I (5 mg/lane), as revealed by anti-FLAG (DDK) mAb
(right). At left, collagen staining by red Ponceau S. In middle, staining of Coll-I a1 and a2 chains or of a2 chain alone by speciﬁc
anti-Coll-I antibodies.
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Figure 5. Interaction of Coll-I with JMJD6 peptides and peptide-induced modulation of collagen properties and cell adhesion. A) ELISA
showing Coll-I binding to JMJD6 peptides seeded in plate (1 mg/well) and incubated with rat Coll-I (50 pM/well) and then with anti-
Coll-I antibody (solid line). Binding of Coll-I on pool of 2 scr peptides (dashed line) as control. B) Effect of JMJD6 peptides on binding
of rJMJD6 to rat Coll-I. Mix of rat Coll-I (0.2 pM/well) and JMJD6 peptide pools (1000 times molar excess) was preincubated for
30 min at 37°C before seeding in plate. Binding of rJMJD6 (50 pM/well) to Coll-I was revealed by anti-FLAG (DDK) mAb. Percentage
of collagen binding was evaluated taking as 100% binding of rJMJD6 to mix Coll-I/scr peptides (means 6 SD, n = 4 separate
experiments; 1-way ANOVA; P, 0.0001). Peptide pool composition shown in Supplemental Fig. S3C. C) In vitro ﬁbrillogenesis assay of
rat Coll-I in presence of JMJD6 peptides was carried out as described in Materials and Methods. Soluble and insoluble ﬁbrillar Coll-I
were separated by SDS-PAGE and respective amounts evaluated by densitometry analysis after gel staining. Amount of soluble Coll-I was
calculated taking as 100% solubility in acetic acid (means6 SD, n = 3 separate experiments; 1-way ANOVA; P = 0.0169). D) Inhibition of
interaction between Coll-I and Fn by JMJD6 peptide pools. Rat Coll-I (0.2 pM/well) premixed 30 min at 37°C with peptide pools
(1000 times molar excess) was seeded in plate. Interaction with Fn (100 nM) detected by incubation with anti-Fn antibody and
expressed as binding percentage with respect to Coll-I mixed to scr peptides (means 6 SD, n = 2 separate experiments; 1-way ANOVA;
P = 0.0215). E) Short-term (2 h) adhesion assay of MDA-MB-231 cells on Coll-I (10 mg/well) premixed in batch with JMJD6 peptide
pools (100 times molar excess). Percentage of adhesion evaluated taking as 100% adhesion value on Coll-I mixed with scr peptides
(means6 SD, n = 2 separate experiments; 1-way ANOVA; P = 0.0006). F) Kinetics of adhesion of MDA-231 cells on Coll-I premixed with
100 times molar excess of JMJD6 peptide pools A–C and I, and scr peptides, tested at 2, 6, and 24 h. Adhesion was evaluated taking as
100% adhesion on Coll-I mixed with scr peptides (means 6 SD, n = 3 separate experiments; 1-way ANOVA; P , 0.0001).
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other Abs or other proteins. Indeed, P4E11 was unable to
recognize rJMJD6 already bound to Coll-I, while the ma-
jority of commercial anti-JMJD6 Abs tested and the anti-
FLAG (DDK) mAb correctly bound JMJD6, regardless of
its interaction with Coll-I (Fig. 6B).
The mutual interference between P4E11 and Coll-I for
binding to rJMJD6was confirmed in an ad hoc assaywhere
P4E11 seeded on a plate interactedwith JMJD6 before, but
not after, addition of Coll-I (Fig. 6C, left). This interference
was specific for P4E11 because the polyclonal aJMJD6 Ab
(Sigma-Aldrich) was unable to compete with Coll-I for its
binding with JMJD6 under the same experimental condi-
tions (Fig. 6C, right). In both cases, JMJD6 was equally
recognized by the polyclonalaJMJD6 (Fig. 6C, left) or anti-
FLAG (DDK) mAbs (Fig. 6C, right) either in the presence
or in the absence ofColl-I. These results demonstrated that
the P4E11 mAb recognizes on JMJD6 a conformational
epitope deputed for interaction with collagen and that the
binding of P4E11 or Coll-I to JMJD6 is mutually exclusive.
This conclusionwas supportedby immunohistochemistry
performed in 2 representative cases of breast carcinoma
where the staining of extracellular JMJD6 by P4E11 mAb
Figure 6. P4E11 mAb recog-
nizes conformational epitope
on rJMJD6 excluding interac-
tion with Coll-I. A) ELISA for
soluble rJMJD6 double recogni-
tion by anti-JMJD6 Abs. Catcher
Abs [P4E11 mAb (P4) or poly-
clonal rabbit (Rb) (Sigma-
Aldrich)] were seeded in plate;
interaction was revealed by incu-
bation with polyclonal Rb aJMJD6
or by mAbs [P4E11, aJMJD6mAb
(Santa Cruz Biotechnology), and
anti-FLAG (DDK)], respectively.
B) Binding of rJMJD6 (10 nM) to
Coll-I in plate (50 pM/well) as
detected by P4E11, anti-FLAG
(DDK), and 4 commercial rab-
bit polyclonal anti-JMJD6 Abs
or secondary Abs alone as
control. C) P4E11 mAb (left)
or polyclonal Rb aJMJD6 Ab
(Sigma-Aldrich) (right) seeded
on plate (1 mg/well) were in-
cubated with rJMJD6 (50 pM/
well). Capability of captured
rJMJD6 to bind rat Coll-I (50, 5,
and 0.5 pM/well) was veriﬁed by
anti-Coll-I polyclonal (left) or
monoclonal (right) Abs (solid
circles), while bound rJMJD6 in
presence (open square) or in
absence (solid triangle) of Coll-I
was monitored by using poly-
clonal anti-JMJD6 Ab (Sigma-
Aldrich) (left) or anti-FLAG
(DDK) mAb (right), respectively.
One representative experiment
of 2 having superimposable re-
sults. D) P4E11 epitope mapping
on JMJD6 protein sequence. Red
indicates amino acid sequences
speciﬁcally protected from enzy-
matic digestion by incubation
with P4E11 mAb; blue, amino
acid stretches bound by both
P4E11 and isotypic control anti-
body. Indicated are amino acid
sequences corresponding to
JMJD6 peptide pools that bind
Coll-I (pools A, C, E, and F) and
are at least partially superimpos-
able to P4E11 epitope (solid line).
JmjC domain is underlined.
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was inversely correlated with the content of Coll-I (Sup-
plemental Fig. S4B, rows 1 and 2, respectively). The same
inverse correlation was also seen in cases of colon carci-
noma and melanoma representative of high and low ex-
pression of JMJD6 detected by P4E11mAb (Supplemental
Fig. S4B, rows 3 and 4, respectively). The staining for Coll-
IV did not correlate with the presence of JMJD6 (Supple-
mental Fig. S4B, right lane).
The mapping of the JMJD6 epitope recognized by
P4E11 confirmed its conformational nature. The epitope
was identified through the sequencing of amino acid
stretches protected from protease digestion due to P4E11-
JMJD6 interaction (Fig. 6D). Three stretches were located
in theN-terminal region. Their sequences corresponded to
aa 14–19 (included in peptides 1–2, pool A), aa 78–84
(peptides 11–12), and aa 114–125 (included in peptides
16–17,poolC). Theother3 sequenceswere identified in the
JmjC domain and corresponded to aa 155–167 (peptides
22–24, with 24 being included in pool E), aa 182–216
(peptides 26–30, with 29–30 being in pool F), and aa
225–252 (peptides 33–35). JMJD6peptides of poolsA,C, E,
and F were involved in Coll-I interaction (Fig. 5A), and
peptides 26 to 27 contained 2 aa, 187 (H/histidine) and 189
(D/aspartic acid), responsible for Fe2+ binding. These re-
sults demonstrate that the P4E11 mAb may have a dual
function: it can block JMJD6 binding to Coll-I, and at the
same time it could inhibit JMJD6 enzymatic activity
through occupancy of the JmjC domain.
In vivo biologic activity of anti-JMJD6
mAb P4E11
It has been recently reported that overexpression of
JMJD6 is associated with poor prognosis in human
breast cancer (24) and other tumor histotypes (37). We
tested whether the P4E11mAb could exert any relevant
biologic effect in vivo using the 4T1 mouse model of
high-grade metastatic breast cancer. Intramammary fat
pad injection of 4T1 cells gave rise to primary tumors of
comparable size in 2 groups of mice treated with either
P4E11 mAb or an isotype-matched control mAb (Fig.
7A). Strikingly, the frequency of metastases in the lung
parenchyma was markedly reduced in P4E11 mAb-
treated mice compared to mice treated with the isotype
control (Fig. 7B). Histology of primary tumors from
P4E11 mAb–treated mice revealed abundant leukocyte
infiltration detected by CD45+ cell staining (Fig. 7C, D);
disarranged stromal fibrovascular septa with consis-
tently reduced collagen content, as revealed by direct
collagen staining and quantification (Fig. 7C, E); Mas-
son trichrome blue staining (Fig. 7C); and less frequent
collagen fiber intersections, according to Gomori retic-
ulin staining of reticular collagen (Fig. 7C). These results
indicate that P4E11-mediated targeting of JMJD6 sig-
nificantly reduced the metastatic burden, possibly in-
terfering with the cell-to-matrix interaction, and also
exerted antifibrotic activity, most likely through the
modulation of collagen content and distribution.
The interference in the JMJD6–collagen interaction
mediated by P4E11 mAb was confirmed in 2 models of
human tumor xenografts:MDA-MB-231breast carcinoma
cells grown in the subcutaneous fat pad (Fig. 7F), and
IGROV1 ovary carcinoma cells forming tumor masses
adherent to the peritoneum (Fig. 7G). In both cases, a re-
duced collagen content and matrix simplification were
observed in tumors from P4E11-treated mice (Fig. 7F, G).
DISCUSSION
The Fe2+- and 2OG-dependent oxygenase family includes
enzymes with different functions, including regulation of
gene expression through epigenetic modifications and
stabilization of collagen chains during collagen synthe-
sis (6). JMJD6, a JmjC domain–containing Fe2+- and
2-oxoglutarate-dependent dioxygenase with histone de-
methylase and lysyl hydroxylase activity, has been
recently associated to tumor progression (38). Here we
demonstrate that JMJD6 can be part of the ECM milieu,
where it binds to Coll-I (a1 chain), and that the Ab-
mediated inhibition of such interaction has antimetastatic
and antifibrotic effects.
To our knowledge, this is the first evidence of JMJD6
expression not confined to the nucleus and cytoplasm, but
present also in the extracellular space as a secreted soluble
protein or associated with the ECM. As for other cyto-
plasmic or nuclear proteins lacking the signal peptide (39),
the release of JMJD6 occurs through an unconventional
mechanism that, insensitive to BFA inhibition, allows its
passage from the cytoplasm to the extracellular milieu.
This is likely to occur through the interaction with mem-
brane phospholipids, such as PA and PS, located at the
surfaceof intracellular vesicles andplasmamembrane (Fig.
3F,G). PShasbeensuggested tobe the ligandof JMJD6 (13).
It is enriched in the luminal leaflet of endoplasmic re-
ticulum and Golgi complex, and it is also expressed at the
cytosolic surface of the endosome/endocytic recycling
compartment (40).Here, PS regulates protein sorting in the
exocytic vesicles (41). In this context, PS could interactwith
cytoplasmic JMJD6, favoring its externalization. Also, PA
regulates exocytosis in several cell types, and itsproduction
by phospholipase D through phosphatidylcholine hydro-
lysis is stimulated by Iono-inducedCa2+ fluxes (42),which,
we show, enhance JMJD6 secretion. PA is present in vesi-
cles such as Rab11-positive recycling endosomes, late
endosomes, andCD63-positive exosomes (43), all ofwhich
costained with the anti-JMJD6 polyclonal Ab. Therefore,
exosomes might represent an additional way to release
JMJD6, as suggested by its presence in the pellet obtained
by ultracentrifugation of MeWo and Jurkat cells’ super-
natant (Fig. 3B and Supplemental Fig. S2A).
We demonstrate that JMJD6 binds to Coll-I, and we
identified the specific sequences that, on JMJD6, are re-
sponsible for this interaction (Figs. 4 and 5A).The possi-
bility that JMJD6 could enzymatically modify Coll-I is
unlikely. In fact, the products of JMJD6 lysyl hydroxylase
activity display C-5 hydroxylysine residues with 5S ste-
reochemistry,while collagen lysyl hydroxylases give lysyl
hydroxylated products with 5R stereochemistry (44). On
thebasis of ourdata,wehypothesize that someaminoacid
sequences present in the JMJD6 peptides and interacting
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Figure 7. Antimetastatic and antiﬁbrotic activity in vivo of anti-JMJD6 P4E11mAb. A) Primary tumor volumes in mice inoculated with 4T1
cells (7 3 103) and treated with P4E11 mAb or with control mAb of same isotype or physiologic solution (untreated). Data derive from
2 separate experiments of 7 animals each. Treatment with control mAb was performed only in 1 of 2 experiments. Differences were
evaluated by Student’s t test and were found to be not statistically signiﬁcant. Median value is indicated. B) Lung metastatic spread of 4T1
cells in same mice evaluated by clonogenic assay. Difference in lung colonies evaluated by 2-tailed Student’s t test: untreated vs. P4E11,
P = 0.0457; mAb control vs. P4E11, P = 0.0003. C) Masson trichrome staining, Gomori reticulin staining, lymphoid inﬁltrate (CD45
staining), and collagen content of representative sample of 4T1 primary tumor from mice treated with physiologic solution (untreated)
or P4E11 mAb. Scale bars, 100 mm. D) Quantitative evaluation of CD45-positive cells and collagen content (E) in 7 samples of 4T1 tumor
treated or not with P4E11 mAb. F) Masson trichrome and Gomori reticulin staining of representative sample of MDA-231 primary tumor
from SCIDmice treated with physiologic solution (untreated) or with P4E11 mAb. Scale bars, 100 mm. G) Masson trichrome and Gomori
reticulin staining of representative sample of peritoneal fragment from nude mice injected with IGROV1 cells and treated with
physiologic solution (untreated) or with P4E11 mAb. Scale bars, 100 mm. Magniﬁcation of extracted areas, 31.5 (F, G), 33 (C).
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with Coll-I interfere with collagen fibrillogenesis and
most likely modulate the interaction of Coll-I with other
ECM proteins, such as Fn (Fig. 3 and Supplemental Fig.
S5). Fn/Coll-I interaction involves specific sequences at
the N terminal of Fn (45) and a binding region on the a1
chain ofColl-I (46).Moreover, collagen fibril formation is
strictly connected with Fn assembly under the cellular
control exerted by interaction with integrins (47). The
complex network of interactions between collagen, Fn,
integrins, and other collagen receptors modulate cell
adhesion and migration. We found that some JMJD6
peptides are able to reduce cell adhesion to Coll-I. No-
tably, the same peptide pools (particularly I and A) ca-
pable of reducing cell adhesion have also been shown to
increase the binding of rJMJD6 to Coll-I and tomodulate
collagen fibrillogenesis (Fig. 5B, C, respectively). In vivo,
reduced cell adhesion caused by JMJD6 might result in
early metastasis and this effect is counteracted by P4E11
mAb, as shown in the 4T1 model of spontaneous me-
tastasis. Moreover, P4E11 showed a marked antifibrotic
activity at the primary site (Fig. 7C, E). Similar to normal
tissues, fibrosis also arises in tumors as a result of
deregulated and uncontrolled ECM synthesis, particu-
larly of collagens (48). In the primary tumor, fibrosis
contributes to tumor progression and enhances meta-
static spread (49). We hypothesize that the P4E11 mAb
inhibits the binding of JMJD6 to Coll-I at the extracellular
level immediately after secretion, which for both JMJD6
and Coll-I is induced by Iono treatment, and before other
profibrotic extracellular modifications of collagen can take
place (50).Moreover, because P4E11mAbdoes not bind to
conformationally altered rJMJD6 nor its peptides, one
possibility is that the interaction of the antibody with the
protein could block ECM matrix metalloproteinase–
mediated JMJD6 digestion. Accordingly, low-molecular-
weight polypeptides recognized by polyclonal anti-JMJD6
Ab are present in the supernatant of 4T1 cells (Supple-
mental Fig. S2A), andwehavepreliminarydata suggesting
that rJMJD6 is susceptible to matrix metalloproteinase en-
zymatic activity in vitro.
In line with other studies where the JMJD6 molecular
interactions and not its enzymatic activity mediate the
protein function (26, 27), our data reveal new biologic
properties of JMJD6 and of JMJD6-derived peptides ap-
parently independent of JmjC-domain activity. However,
the peculiar characteristics of P4E11mAb in recognizing a
conformational target epitope, which also includes amino
acid sequences of the JmjC domain, do not exclude the
notion that in vivo, a wide range of activities might be
modulated by the antibody, including the JMJD6 enzy-
matic activity itself. For all these reasons, the anti-JMJD6
mAb P4E11 may represent a new opportunity to target
fibrotic and tumor diseases.
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